ArticleBMC cancer2025
Long-term outcomes and survival rates of renal cell carcinoma patients in Erbil, Iraq: a follow-up study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A systematic review of the latest progress of drug resistance and clinical application of immunotherapy in renal cell carcinoma in the past five years based on bibliometrics.Human vaccines & immunotherapeutics · 2025Pooled it
- Frailty and survival of patients with renal cell carcinoma: A meta-analysis.Biomolecules & biomedicine · 2025Pooled it
- Delayed diagnostic imaging but stable treatment initiation for kidney cancer during the COVID-19 pandemic: a Hungarian cohort study.Pathology oncology research : POR · 2026Article
- Optimizing outcomes of partial nephrectomy in patients with tumors in solitary kidneys: a non-systematic review.Journal of medicine and life · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRenal cell carcinoma (RCC) is a heterogeneous group of cancers originating from renal tubular and epithelial cells, constituting 2-4% of global cancer cases. Incidence patterns vary internationally, with the Czech Republic and European Baltic countries experiencing higher rates. Despite the majority of cases being sporadic, approximately 4% have a hereditary basis.
methodsThis study, conducted in Erbil, Iraq, investigates RCC survival rates and influential factors at Nanakaly Hospital and Rizgary Oncology Center. A retrospective analysis spanning January 2017 to December 2020, covering 93 patients, explores demographic, clinical, and treatment variables.
resultsOut of a total of 93 cases, there were 68 deaths, and 25 cases were censored. This means that 73.12% of the cases resulted in death, and 26.88% of the cases were censored. The Kaplan-Meier survival analysis indicates a mean survival time of approximately 5.517 years. Clinical characteristics such as tumor side and histology show no significant associations with survival status, except for the TNM stage (p-value < 0.001). While smoking, alcohol history, history of malignancy, and comorbidities demonstrate no significant impact on survival, the study identifies a potential trend associating comorbidities with poorer outcomes (p-value = 0.051). Significant associations emerge with treatment types; radical nephrectomy (p-value = 0.004) and systemic treatments (p-value < 0.001) influence survival. Strikingly, recurrence was significantly associated with mortality (p-value < 0.001).
conclusionsThe study reveals a higher RCC had a shorter survival in Erbil compared to international survival. This is attributed to delayed referrals and advanced disease stages. Additionally, the absence of crucial antineoplastic agents negatively affects outcomes. Comorbidities are also found to significantly reduce survival rates. These findings underscore the necessity for an enhanced referral system, improved access to oncological services, and the approval of essential therapies in Erbil.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.